September 10, 2025DiagnosticsOpen Access

Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD)

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Literature review reveals moderate efficacy of immunomodulatory therapies in SSc-ILD, highlighting safety concerns.

Clinical studies show improvements in lung function parameters in patients with systemic scleroderma and ILD.
Nintedanib and tocilizumab demonstrate promising results in reducing FVC decline and stabilizing pulmonary function.
Immunosuppressants like cyclophosphamide and mycophenolate mofetil have shown moderate to good efficacy in SSc-ILD.
There is a critical need for well-designed, multicenter trials to assess the long-term outcomes of therapies for SSc-ILD.

Piecuch et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark